联交所在作出该决定时，就本集团的业务规模、财务状况、资产组成及主要业务项目的进展情况等方面 进行了整体评估，并认为本集团现时的运营规模及资产基础水平并不足以支持其持续上市地位。 星太链集团(00399)发布公告，于2025年11月24日，本公司已根据上市规则第2B章提交书面要求，以将 该决定转交联交所上市委员会复核(复核)。因此，本公司股份将继续买卖。 ...

联交所在作出该决定时，就本集团的业务规模、财务状况、资产组成及主要业务项目的进展情况等方面 进行了整体评估，并认为本集团现时的运营规模及资产基础水平并不足以支持其持续上市地位。 智通财经APP讯，星太链集团(00399)发布公告，于2025年11月24日，本公司已根据上市规则第2B章提 交书面要求，以将该决定转交联交所上市委员会复核(复核)。因此，本公司股份将继续买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 要求覆核聯交所根據第13.24條作出之決定 本公告由星太鏈集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條 及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上 市規則）作出。 茲提述本公司日期為二零二五年十一月十七日之公告，內容有關聯交所因本 公司未能根據上市規則第13.24條的規定維持足夠的運營水平以令其股份得以 繼續上市，且受限於本公司的覆核權，將根據上市規則第6.01(3)條暫停本公司 股份買賣之決定（「該決定」）。 本公司正與債券持有人就二零二五年七月二十八日到期的可換股債券的 延期及重組進行最後階段的磋商。 ...

格隆汇11月19日丨星太链集团(00399.HK)公布，董事会会议将于2025年11月28日星期五举行，以考虑及 批准(其中包括)公司及其附属公司截至2025年9月30日止六个月之综合中期业绩。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 董事會會議通告 請同時參閱本公告於本公司網站 w w w .starcoingroup.com 及 www.irasia.com/listco/hk/ starcoingroup 刊 載之內容。 星太鏈集團有限公司（「本公司」）董事會（「董事會」）謹此公佈，董事 會會議將於二零二五年十一月二十八日星期五舉行，以考慮及批准（其中包 括）本公司及其附屬公司截至二零二五年九月三十日止六個月之綜合中期業 績。 承董事會命 星太鏈集團有限公司 主席 仰融 香港，二零二五年十一月十九日 於本公告日期，董事會包括仰融博士（主席兼執行董事）、高源興先生（執行董事）、唐榕先生 （執行董事）、齊淑娟女士（執行董事）、龍凡博士（執行董事）、伍鳴博士（執行 ...

Key Points - A total of 45 stocks reached their 52-week highs as of the market close on November 17, with notable performers including China National Biotech Group (08247), Doumeng Technology (01917), and Century United Holdings (01959) achieving high rates of 55.17%, 48.72%, and 33.70% respectively [1] - The highest closing prices for the top three stocks were 1.700, 0.099, and 2.270, with their peak prices being 1.800, 0.116, and 2.420 respectively [1] - Other significant stocks that reached new highs include Jingyang Group (08257) with a high rate of 27.66% and Hongji Group Holdings (01718) at 22.22% [1] - The report also highlights stocks that reached their 52-week lows, with Starry Chain Group (00399) experiencing a significant decline of 59.31% [2] - Other notable decliners include Xingkong Huawen (06698) and Limo Technology (02405) with declines of 13.79% and 13.46% respectively [2] - The data indicates a mixed performance in the market, with some stocks achieving significant gains while others faced substantial losses [2][3]

整体看，市场处于消化压力、寻找新平衡的阶段。资金在高股息防御品种、区域性政策主题和超跌的科技龙头之间进行再配置。 11月17日，A股震荡调整，沪指跌0.43%，深成指跌0.35%，创业板跌0.8%。福建本地股、军工、锂矿、AI应用等板块领涨；贵金属、医药、光伏 设备、培育钻石等板块领跌。 具体来看，福建本地股持续走强，三木集团、平潭发展等近20股涨停，资金对区域经济主题的追捧正进入白热化阶段。 锂电板块反复活跃，盛新锂能、融捷股份等封板，延续了上周的强势。尽管龙头宁德时代因股东减持低开，但板块整体依然强势，消息面上，锂 电材料涨价潮持续传导，氯化亚砜迎来价格猛涨。 军工股盘中拉升，长城军工、航天发展等涨停。消息面上，外交部、文旅部、教育部等多部门重要提醒，近期避免前往日本，日本公然发表挑衅 言论，严重恶化中日人员交流氛围。中泰证券表示，日方挑衅使得地缘局势不确定性加剧，可能成为"推动祖国统一"的一大隐患，在我国核心利 益受到外部威胁的情况下，国防建设投入有望持续加大，规划目标有望加速实现，将推动我国军工产业进一步高质量发展。 AI应用概念走强，三六零、宣亚国际等多股涨停。在经历调整后，资金再度回流至具备想象空 ...

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].

Core Viewpoint - Star Chain Group (00399.HK) experienced a significant decline in its stock price, dropping over 70% in early trading, with a current decrease of 66.81%, trading at 0.079 HKD, and a transaction volume of 7.6626 million HKD [1] Company Summary - Star Chain Group's stock price fell by more than 70% in early trading [1] - As of the latest update, the stock is down 66.81% [1] - The current trading price is 0.079 HKD [1] - The total transaction volume reached 7.6626 million HKD [1]